Rebif Sales Hold Up As Merck KGaA Looks For Acquisitions, Partnerships
This article was originally published in The Pink Sheet Daily
Executive Summary
The diversified German company battled currency exchange headwinds and reduced royalty income in the first quarter of 2014, but Rebif sales were better than expected in the face of increasing competition from new oral MS therapies.